Rayner launches T-flex® Aspheric Toric IOL in China

For immediate release

18 August 2014. Hove, United Kingdom. Rayner Intraocular Lenses Limited, the pioneering manufacturer of intraocular lenses, proudly announced today that the T-flex Aspheric Toric intraocular lens (IOL) has received Chinese Food and Drug Administration (CFDA) approval and is being launched in China.

Product Approval Details

The CFDA granted regulatory approval and sale of the T-flex Aspheric Toric IOL (623T) in the following power range:

Spheres: -10.0 to +24.0 D in 0.5 D steps
Cylinders: +1.0 to +11.0 D in 0.5 D steps

T-flex Aspheric is a hydrophilic acrylic toric IOL, indicted for the treatment of cataract patients with pre-existing corneal astigmatism, and has been successfully implanted for over 10 years in many other key global markets.

In addition to Rayner’s complete range of spherical and aspheric monofocal IOLs, Chinese surgeons will now have access to the company’s toric platform - a key product in Rayner’s premium IOL portfolio.

Rayner’s Commercial Director, Mark Norris, explains “We are delighted to have the China SFDA (CFDA) approval certificate for T-flex Aspheric confirmed. Rayner is already strong in China and to add the T-flex Aspheric IOL to our offering allows us to continue our product launch strategy in current markets.”

In addition to the T-flex Aspheric Toric IOL, Rayner’s primary lens portfolio also consists of monofocal, multifocal and multifocal-toric IOLs. Rayner also offers the Sulcoflex® pseudophakic supplementary range of IOLs, designed for ciliary sulcus implantation, indicated for treating residual ametropia and presbyopia after primary capsular bag IOL surgery.

For further information and availability regarding the T-flex Aspheric Toric IOL, or Rayner’s full lens portfolio, please contact your local sales representative or distributor.

-ENDS-

Rayner, the pioneering intraocular lens (IOL) manufacturer has over 60 years of dedication to improving vision and the restoration of sight worldwide. Today, Rayner’s mission remains that of delivering innovative and clinically superior ophthalmic products that consistently respond to the expectations of our global customers and reward the profound trust placed in the Company to improve sight and quality of life.

Headquartered in Hove, East Sussex, United Kingdom, Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 70 countries and a direct sales team in the United Kingdom, USA, Germany and Austria.

For questions or to schedule an interview with a Rayner representative, please contact Rayner at iol_enquiries@rayner.com